GlassScriptPhysician profile
Danielle Denise Grant
NPI 1548436496
$2,141.70
in general payments reported to CMS, 2019-2025
30 companies · $153 in 2025
The $153 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $242 · 2021: $167 · 2022: $533 · 2023: $377 · 2024: $297 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $521.74 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $281.54 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $198.49 | 2019-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $154.87 | 2020-2021 | |
| Cranial Technologies, INC | $93.34 | 2019-2023 | Doc Band |
| Pfizer INC. | $87.11 | 2019-2022 | |
| Glaxosmithkline, LLC. | $75.46 | 2022-2025 | Bexsero, Rotarix, Pediarix |
| Merck Sharp & Dohme LLC | $67.34 | 2022-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Vertical Pharmaceuticals, LLC | $64.16 | 2019-2025 | Relexxii |
| Sanofi Pasteur INC. | $56.51 | 2019-2021 | |
| Neos Therapeutics, LP | $51.60 | 2019 | |
| Noven Therapeutics, LLC | $42.78 | 2024-2025 | Xelstrym |
| Adlon Therapeutics L.P. | $41.93 | 2019-2020 | |
| Genentech USA, INC. | $37.76 | 2019-2020 | |
| Chiesi USA, INC. | $33.27 | 2024 | Filsuvez |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries LP | $30.58 | 2022-2023 | |
| Integra Lifesciences Corporation | $28.75 | 2024 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Arbor Pharmaceuticals, INC. | $28.13 | 2019-2020 | |
| Sobi, INC | $26.46 | 2019 | |
| Supernus Pharmaceuticals, INC. | $25.61 | 2024 | Qelbree |
| Acclarent, INC | $25.19 | 2019 | |
| Phadia US INC. | $23.95 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.40 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $20.60 | 2023 | Firdapse |
| Seqirus USA INC | $20.52 | 2022 | |
| Collegium Pharmaceutical, INC. | $18.05 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $17.08 | 2024 | Ycanth |
| Shire North American Group INC | $16.71 | 2019 | |
| Smith+Nephew, INC. | $15.55 | 2019 | |
| Aytu Biopharma, INC. | $14.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Grant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.